In vivo detection of choline in ovarian tumors using 3D magnetic resonance spectroscopy

Investigative Radiology

Volumn 46, Issue 6, 2011, Pages 377-382

  Esseridou, Anastassia ^a   Di Leo, Giovanni ^a   Sconfienza, Luca M ^a   Caldiera, Valentina ^b   Raspagliesi, Francesco ^c   Grijuela, Barbara ^c   Hanozet, Francesco ^c   Podo, Franca ^d   Sardanelli, Francesco ^b  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

chemical shift imaging; magnetic resonance spectroscopy; Ovarian cancer

Indexed keywords

CHOLINE; GADOTERATE MEGLUMINE;

AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; ENDOMETRIOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; NUCLEAR MAGNETIC RESONANCE; OVARY CANCER; OVARY CYST; OVARY TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; THECOMA; THREE DIMENSIONAL IMAGING; THREE DIMENSIONAL PHOTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 79955854175     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31821690ef     Document Type: Article

References (35)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-781.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
3. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361:170-177.
4. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006;107:1399-1410. (Pubitemid 44336908)
5. Booth SJ, Turnbull LW, Poole DR, et al. The accurate staging of ovarian cancer using 3T magnetic resonance imaging-a realistic option. BJOG. 2008;115:894-901. (Pubitemid 351692995)
6. Glunde K, Artemov D, Penet MF, et al. Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev. 2010;110:3043-3059.
7. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst. 2002;94:1197-1203. (Pubitemid 34993869)
8. Tse GM, Yeung DK, King AD, et al. In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat. 2007; 104:249-255. (Pubitemid 47231271)
9. Sardanelli F, Fausto A, Di Leo G, et al. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. Am J Roentgenol. 2009;192:1608-1617.
10. Ackerstaff E, Pflug BR, Nelson JB, et al. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61:3599-3603. (Pubitemid 32694969)
11. Chen AP, Cunningham CH, Kurhanewicz J, et al. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging. 2006;24:825-832. (Pubitemid 44205376)
12. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol. 2007;63:351-360. (Pubitemid 47321931)
13. Mori N, Delsite R, Natarajan K, et al. Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline. Mol Imaging. 2004;3:319-323. (Pubitemid 40245453)
14. Wang CK, Li CW, Hsieh TJ, et al. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology. 2004; 232:599-605.
15. Iorio E, Mezzanzanica D, Alberti P, et al. Alterations of choline metabolism in ovarian tumor progression. Cancer Res. 2005;65:9369-9376. (Pubitemid 41508005)
16. Spadaro F, Ramoni C, Mezzanzanica D, et al. Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res. 2008;68:6541-6549.
17. Iorio E, Ricci A, Bagnoli M, et al. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 2010;70: 2126-2135.
18. 1H-MRS in vivo at 3T. Magn Reson Med. 2009;62:855-861.
19. Turnbull L, Booth S. MR imaging of gynecologic diseases at 3T. Magn Reson Imaging Clin N Am. 2007;15:403-431. (Pubitemid 47430007)
20. Moonen CTW, van Zijl PCM. Highly effective water suppression for in vivo proton NMR spectroscopy. J Magn Reson. 1990;88:28-41.
21. Wallace JC, Raaphorst GP, Somorjai RL, et al. Classification of 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis. Magn Reson Med. 1997;38:569-576. (Pubitemid 27419221)
22. Okada T, Harada M, Matsuzaki K, et al. Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. J Magn Reson Imaging. 2001; 13:912-917. (Pubitemid 32479950)
23. Stanwell P, Russell P, Carter J, et al. Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla. Invest Radiol. 2008;43:745-751.
24. Booth SJ, Pickles MD, Turnbull LW. In vivo magnetic resonance spectros-copy of gynaecological tumours at 3.0 Tesla. BJOG. 2009;116:300-303.
25. Salibi N, Brown MA. Clinical MR Spectroscopy. New York, NY: Wiley-Liss; 1998.
26. Podo F, Sardanelli F, Iorio E, et al. Abnormal choline phospholipid metabolism in breast and ovary cancer: molecular bases for noninvasive imaging approaches. Curr Med Imaging Rev. 2007;3:123-137. Available at:www. ingentaconnect.com:80/content/ben/cmir/2007/00000003/00000002/ art00006. (Pubitemid 46773873)
27. Sardanelli F, Fausto A, Podo F. MR spectroscopy of the breast. Radiol Med. 2008;113:56-64. (Pubitemid 351387211)
28. Canese R, Iorio E, Ricci A, et al. Metabolite quantification in tumors by magnetic resonance spectroscopy: objectives, results and perspectives. Curr Med Imaging Rev. 2009;5:110-127.
29. Stanwell P, Gluch L, Clark D, et al. Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T. Eur Radiol 2005;15:1037-1043. (Pubitemid 41166737)
30. Wilson JMG, Junger G. Principles and practice of screening for disease. Geneva, CH: World Health Organization; 1968.
31. Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol. 2010;45:15-23.
32. Boss A, Kolb A, Hofmann M, et al. Diffusion tensor imaging in a human PET/MR hybrid system. Invest Radiol. 2010;45:270-274.
33. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89. (Pubitemid 46535708)
34. Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol. 2007;17:873-887. (Pubitemid 46766869)
35. Lenkinski RE, Wang X, Elian M, et al. Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast. Magn Reson Med. 2009;61:1286-1292.